Current:Home > FinanceFDA approves Opill, the first daily birth control pill without a prescription -CapitalSource
FDA approves Opill, the first daily birth control pill without a prescription
View
Date:2025-04-15 14:55:19
The Food and Drug Administration approved a daily oral contraceptive pill for use without a prescription on Thursday, a landmark event that comes as some U.S. states have sought to restrict access to birth control and abortion.
The move clears the way for Opill (norgestrel), which comes in tablet form, to be sold over the counter in a wide range of venues, from online markets to drug stores, convenience stores and grocery stores.
"Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said in a statement.
When used as directed, she added, daily oral contraception such as Opill "is safe and is expected to be more effective than currently available nonprescription contraceptive methods in preventing unintended pregnancy."
Opill is made by Perrigo, which has its headquarters in Dublin. Opill is deemed a "progestin-only" pill, made with "a synthetic version of the hormone progesterone to prevent pregnancy," as NPR has reported, noting that most birth control pills also contain estrogen.
"Today marks a truly momentous day for women's health nationwide," said Perrigo President and CEO Patrick Lockwood-Taylor, adding that his company's product "has the potential to radically transform women's access to contraception."
As for when the pills — sold in boxes containing a 28-day supply — will hit the market, the FDA says the timeline is up to Perrigo. The company says the pills will be available in stores and online early in the first quarter of 2024. Pricing hasn't been released.
"Other approved formulations and dosages of other oral contraceptives will remain available by prescription only," the FDA said.
veryGood! (74)
Related
- Average rate on 30
- Why '90s ads are unforgettable
- U.S. Coast Guard and cruise line save 12 passengers after boat sinks near Dominican Republic
- American Girl doll live-action movie in the works with Mattel following 'Barbie' success
- Macy's says employee who allegedly hid $150 million in expenses had no major 'impact'
- 'Wonka' returns with more music, less menace
- 2023 was a great year for moviegoing — here are 10 of Justin Chang's favorites
- How the deep friendship between an Amazon chief and Belgian filmmaker devolved into accusations
- A South Texas lawmaker’s 15
- Dwayne Johnson to star in Mark Kerr biopic from 'Uncut Gems' director Benny Safdie
Ranking
- 'No Good Deed': Who's the killer in the Netflix comedy? And will there be a Season 2?
- Missile fired from rebel-controlled Yemen misses a container ship in Bab el-Mandeb Strait
- Amazon, Target and Walmart to stop selling potentially deadly water beads marketed to kids
- Australia cricketer Khawaja wears a black armband after a ban on his ‘all lives are equal’ shoes
- Don't let hackers fool you with a 'scam
- Veteran Taj Gibson rejoining New York Knicks, reuniting with Thibodeau
- American Girl doll live-action movie in the works with Mattel following 'Barbie' success
- Woman and man riding snowmachine found dead after storm hampered search in Alaska
Recommendation
Don't let hackers fool you with a 'scam
'The Crown' ends as pensive meditation on the most private public family on Earth
CBS News poll analysis: Some Democrats don't want Biden to run again. Why not?
2023: The year we played with artificial intelligence — and weren’t sure what to do about it
The company planning a successor to Concorde makes its first supersonic test
Experts at odds over result of UN climate talks in Dubai; ‘Historic,’ ‘pipsqueak’ or something else?
Congress passes contentious defense policy bill known as NDAA, sending it to Biden
The Shohei Ohani effect: Jersey sales, ticket prices soar after signing coveted free agent